The combination therapy of atezolizumab, a monoclonal antibody targeting PD-L1, and bevacizumab, a monoclonal antibody, against vascular endothelial growth factor (VEGF) A significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with unresectable HCC in the IMbrave 150 phase 3 clinical trial [8]. Here, VEGFA is linked to hepatocellular carcinoma.